Mapping analysis to predict SF-6D utilities from health outcomes in people with focal epilepsy

India Flint (), Jasmina Medjedovic, Ewa Drogon O’Flaherty, Elena Alvarez-Baron, Karthinathan Thangavelu, Natasa Savic, Aurelie Meunier and Louise Longworth
Additional contact information
India Flint: PHMR Limited
Jasmina Medjedovic: Arvelle Therapeutics GmbH
Ewa Drogon O’Flaherty: Arvelle Therapeutics GmbH
Elena Alvarez-Baron: Arvelle Therapeutics GmbH
Karthinathan Thangavelu: Arvelle Therapeutics GmbH
Natasa Savic: Arvelle Therapeutics GmbH
Aurelie Meunier: PHMR Limited
Louise Longworth: PHMR Limited

The European Journal of Health Economics, 2023, vol. 24, issue 7, No 5, 1072 pages

Abstract: Abstract Background Focal-onset seizures (FOS) are commonly experienced by people with epilepsy and have a significant impact on quality of life (QoL). This study aimed to develop a mapping algorithm to predict SF-6D values in adults with FOS for use in economic evaluations of a new treatment, cenobamate. Methods An online survey, including questions on disease history, SF-36, and an epilepsy-specific measure (QOLIE-31-P) was administered to people with FOS in the UK, France, Italy, Germany, and Spain. A range of regression models were fitted to SF-6D scores including direct and response mapping approaches. Results 361 individuals were included in the analysis. In the previous 28 days, the mean number of FOS experienced was 3, (range 0–43) and the mean longest period of consecutive days without experiencing a seizure was 14 days (range 1–28 days or more). Mean responses on all SF-36 dimensions were lower than general population norms. Mean SF-6D and QOLIE-31-P scores were 0.584 and 45.72, respectively. The best performing model was the ordinary least squares (OLS), with root mean squared error and mean absolute error values of 0.0977 and 0.0742, respectively. Explanatory variables which best predicted SF-6D included seizure frequency, severity, freedom, and age. Conclusion People with uncontrolled FOS have poor QoL. The mapping algorithm enables the prediction of SF-6D values from clinical outcomes in people with FOS. It can be applied to outcome data from clinical trials to facilitate cost-utility analysis.

Keywords: Health-related utility; Mapping; SF-6D; SF-36; Epilepsy; Quality of life; Cenobamate (search for similar items in EconPapers)
JEL-codes: B40 C12 C13 C15 C19 C30 C51 C52 C53 C55 C83 C87 (search for similar items in EconPapers)
Date: 2023
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s10198-022-01519-w Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:eujhec:v:24:y:2023:i:7:d:10.1007_s10198-022-01519-w

Ordering information: This journal article can be ordered from
http://www.springer. ... cs/journal/10198/PS2

DOI: 10.1007/s10198-022-01519-w

Access Statistics for this article

The European Journal of Health Economics is currently edited by J.-M.G.v.d. Schulenburg

More articles in The European Journal of Health Economics from Springer, Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ) Contact information at EDIRC.
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().